about
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinibThe homeotic protein Six3 is a coactivator of the nuclear receptor NOR-1 and a corepressor of the fusion protein EWS/NOR-1 in human extraskeletal myxoid chondrosarcomasMerlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleusWNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasisMolecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancersMET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinibSomatic mutations affect key pathways in lung adenocarcinomaCharacterizing the cancer genome in lung adenocarcinoma.Cloning of an Alpha-TFEB fusion in renal tumors harboring the t(6;11)(p21;q13) chromosome translocationMolecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for MolecularFrequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma.Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas.Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skippingAcquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain.The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancersMolecular detection of JAZF1-JJAZ1 gene fusion in endometrial stromal neoplasms with classic and variant histology: evidence for genetic heterogeneityIdentification of PAX3-FKHR-regulated genes differentially expressed between alveolar and embryonal rhabdomyosarcoma: focus on MYCN as a biologically relevant targetNovel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitorsE-cadherin mutation and Snail overexpression as alternative mechanisms of E-cadherin inactivation in synovial sarcomaEpigenetic and genetic loss of Hic1 function accentuates the role of p53 in tumorigenesisAllelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor geneAnalysis of genetic variants in never-smokers with lung cancer facilitated by an Internet-based blood collection protocol: a preliminary reportHigh expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-IGF-1R antibody (R1507)Molecular Detection of JAZF1-JJAZ1 Gene Fusion in Endometrial Stromal Neoplasms with Classic and Variant HistologyThe landscape of somatic copy-number alteration across human cancers.EWS-FLI1 and Ewing's sarcoma: recent molecular data and new insights.Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials.Validation of the 2-DeltaDeltaCt calculation as an alternate method of data analysis for quantitative PCR of BCR-ABL P210 transcripts.Integrative subtype discovery in glioblastoma using iCluster.Genomic aberrations frequently alter chromatin regulatory genes in chordoma.Imatinib mesylate in Philadelphia chromosome-positive leukemia of childhood.Functional copy-number alterations in cancer.Integrative clustering of multiple genomic data types using a joint latent variable model with application to breast and lung cancer subtype analysis.Reduced NF1 expression confers resistance to EGFR inhibition in lung cancerMorphologic features of adenocarcinoma of the lung predictive of response to the epidermal growth factor receptor kinase inhibitors erlotinib and gefitinib.Integrating Genomics Into Clinical Pediatric Oncology Using the Molecular Tumor Board at the Memorial Sloan Kettering Cancer Center.Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA.Genomic and mutational profiling to assess clonal relationships between multiple non-small cell lung cancers.Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy.
P50
Q21563446-5A4D5FCE-D9ED-4DDD-87E4-290990D0ADEFQ24293141-CCBE557E-7E0D-417F-B503-311B9C71FB7FQ24300770-97B26002-38B6-429F-810C-7EEB9D9221D2Q24310644-1ECB32BA-64F9-4C41-BABC-AD3731267415Q24611043-AB0CA6AE-EDC5-4E24-93B4-235F6CAD1CE0Q24646295-0A9ED0EE-3C11-4A21-B241-8A5E10CF0C25Q24648102-C4631CE9-7E3E-410E-A664-23A30801EC65Q24649926-64D2EED9-DB30-4216-94D6-B116E601DABDQ24675000-F07DAA35-1439-4277-8709-965417C2241BQ26828860-9769E9E8-E033-4C78-BC1E-28A4A50C5CCCQ27851448-4E745C33-DCDB-4235-87DA-545FC00B61A0Q27851860-A5E677F9-5A0C-4D29-BCD1-A9C4AC0D0FDFQ27852116-18DBC3C9-E947-42B9-B5C2-49B9DD74E396Q27853167-F4CF0917-A382-4078-9130-87B2948A202EQ27853190-61C6DB22-0717-4279-B26A-5EF8B78B971CQ28115840-F4166262-0F84-4CFC-A781-C8B634EC9E0DQ28252604-2E3D82A8-86B9-41C1-81D4-5CEFC82CE6A5Q28272405-66D29413-E53F-45CB-96EA-748645AD0779Q28272463-EEED0676-5532-4CB8-995F-D5C155A6CD42Q28286408-9DE70DE0-39A9-4156-8D24-BF8BC728E98EQ28288212-14C90225-BD99-420B-8D6F-2E0AEAEE994DQ28307186-1A73FD29-920D-48EA-B97D-A51EF21CB78EQ28393099-A11AACCC-6A48-414B-B48B-6DB6CA11AB5AQ28476277-C5EC6AA1-4D73-4BD3-90A7-429A51581249Q29391782-3E94B1A9-DE07-4438-98EA-7F33849C0AD7Q29547648-0765DA42-8C71-4F4B-991E-036C19638727Q30746507-B9F3A64C-ACF9-47F8-88B2-AF31DBAC88FBQ30783484-D9ACB1EA-9F5A-4B1C-BE1C-99F042340A76Q31034100-0A14651F-6CA3-48EC-B600-65C59B4A24A6Q31059566-13DF3F0E-0D51-400B-84F3-A963CCC6A00EQ33275983-5B276F98-64D0-4A2E-BCDE-20DD0C006AA7Q33358095-741C4F6E-F750-4F7F-AB97-0D9D85116E66Q33368629-4E89E288-F1E6-4C1C-B49E-D1E7A30C5054Q33503982-9EA69476-7518-4345-B1D3-D7C8E4F0F3CEQ33572728-449D2AD8-CBED-4DF9-81BE-06189FD924E8Q33594324-BF06FFCF-014B-4595-9810-7DDF10CCC5EEQ33677392-B8DDC929-36E3-4131-AD20-C964E6893C76Q33817011-5DB7931B-B2BA-417A-AD80-0989DC07B70EQ33941217-01660B75-A9E3-47F3-AD59-0F3F61762BD7Q34026081-03C6ECD5-88F8-43E9-A44D-2D734E511115
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Marc Ladanyi
@ast
Marc Ladanyi
@en
Marc Ladanyi
@es
Marc Ladanyi
@nl
Marc Ladanyi
@sl
type
label
Marc Ladanyi
@ast
Marc Ladanyi
@en
Marc Ladanyi
@es
Marc Ladanyi
@nl
Marc Ladanyi
@sl
prefLabel
Marc Ladanyi
@ast
Marc Ladanyi
@en
Marc Ladanyi
@es
Marc Ladanyi
@nl
Marc Ladanyi
@sl